• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

House Speaker’s Drug-Pricing bill would Save Medicare $345B, CBO says

Share:

October 16, 2019

The drug-pricing bill proposed by House Speaker Nancy Pelosi, D-Calif., could save Medicare up to $345 billion over seven years, according to a new estimate by the Congressional Budget Office.

The bill, introduced in September, would allow the HHS secretary to negotiate with drug manufacturers the prices of up to 250 drugs annually. It also would set an upper limit on drug prices, only allowing them to reach up to 120 percent of the average price paid in other economically similar countries.

If drugmakers refuse to negotiate, their gross sales would be taxed starting at 65 percent.

The CBO estimates the proposal would bring big savings to U.S. taxpayers and have wide-ranging effects on the drug industry, including a hike in drug prices in other countries to compensate for lower prices in the U.S.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Drugmakers could also introduce medications at higher prices to try to offset any discounts and decrease new drug development, the CBO said.

Source: Becker’s Hospital Review

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Doctor Anywhere Partners with ViettelPay to Provide Online Healthcare Services in VietnamDoctor Anywhere Partners with ViettelPay to Provide Online Healthcare Services in Vietnam
  • Karo Pharma To Acquire Trimb Healthcare from Avista Capital PartnersKaro Pharma To Acquire Trimb Healthcare from Avista Capital Partners
  • Vitamin Shoppe (+41%) to be Acquired For $6.50 Per ShareVitamin Shoppe (+41%) to be Acquired For $6.50 Per Share
  • Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera TherapeuticsLexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics
  • Pfizer pays BioNTech $120M upfront to form mRNA flu vaccine pactPfizer pays BioNTech $120M upfront to form mRNA flu vaccine pact
  • GENFIT Drops up to $105M for Versantis to up Liver GameGENFIT Drops up to $105M for Versantis to up Liver Game
  • How AR and MR Technology Can Reduce Medical Vulnerability to Improve the Patient ExperienceHow AR and MR Technology Can Reduce Medical Vulnerability to Improve the Patient Experience
  • Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung BioepisBiogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications